Sector Expert: John McCamant

Medical Technology Stock Letter

Image: John McCamant

John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter. McCamant has spent 25 years on the frontlines of biotechnology investing. He has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.

Subscribe to
Streetwise Reports

Companies Commented On

  • Myovant Sciences Ltd.
  • Nektar Therapeutics


Recent Interviews

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing (11/15/17)
golden-pill-of-dollars630

Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.

Drug Offers 'Best-in-Class' Potential (11/1/17)
moleculebeaker580

John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health.

Fallen Biotech Angels to Arise: John McCamant and Jay Silverman of the Medical Technology Stock Letter (9/16/15)
multicoloredbeakers580

It's all about data for John McCamant and Jay Silverman of the Medical Technology Stock Letter, and right now it's festival time as we approach the busy season of market-moving catalysts and milestones. From now until December, biotech investors will be focused on the press releases, webinars and scientific presentations that serve as a vitality tonic for the entire biotech industry. In this interview with The Life Sciences Report, McCamant and Silverman give a detailed picture of their growth theories on six biotech stocks that could reap many multiples on invested capital over the next few years.

Recent Quotes

"CBMG is putting together a huge portfolio of assets in cancer."

The Life Sciences Report Interview with John McCamant (9/16/15)
more >

"CBMG's world-class pipeline is still below Wall Street's radar."

— John McCamant, Medical Technology Stock Letter (6/11/15)
more >

"CBMG is a recently transformed company."

The Life Sciences Report with John McCamant (5/12/15)
more >

"We continue to believe that OGXI is undervalued."

— John McCamant, Medical Technology Stock Letter (12/21/12)
more >

"The potential of CYCC's phase 3 trial with AML gives the Street more confidence."

The Life Sciences Report Interview with John McCamant (10/25/12)
more >

"If OGXI-011 starts delivering in phase 3, OGXI could be a five- or tenbagger."

The Life Sciences Report Interview with John McCamant (10/4/12)
more >

"We continue to believe that OGXI is undervalued."

— John McCamant, Medical Technology Stock Letter (7/20/12)
more >

"Data from OGXI's phase 2 trial for OGX-427 is encouraging."

— John McCamant, Medical Technology Stock Letter (6/8/12)
more >



Due to permission requirements, not all quotes are shown.